Taxodione Inhibits Glioblastoma Proliferation and Potentiates the Cytotoxicity of Paclitaxel

Area of Science:

• Neuro-oncology
• Molecular Biology
• Pharmacology

Background:

• Glioblastoma develops resistance to genotoxic therapy by increasing stem-cell-like properties.
• Farnesyl diphosphate synthase (FDPS) is crucial for maintaining these stem-cell features.
• Developing CNS-permeable FDPS inhibitors is critical for effective glioblastoma treatment.

Purpose of the Study:

• To investigate taxodione, a potential CNS-permeable FDPS inhibitor, for glioblastoma therapy.
• To evaluate taxodione's efficacy against glioblastoma stem-cell-like characteristics.
• To compare taxodione with its congener and a known FDPS inhibitor.

Main Methods:

• Treatment of U87MG glioblastoma cells with taxodione, 7-(2'-oxohexyl)-taxodione, and a known FDPS inhibitor.
• Assessment of tumor spheroid size reduction in a dose- and time-dependent manner.
• Analysis of FDPS inhibition and mevalonate pathway gene expression.

Main Results:

• Taxodione significantly reduced glioblastoma tumor spheroid size.
• This effect was dose- and time-dependent and linked to FDPS inhibition.
• Taxodione downregulated mevalonate pathway genes and sensitized cells to paclitaxel.

Conclusions:

• Taxodione is a promising neuro-oncology drug candidate for glioblastoma.
• Its mechanism involves FDPS inhibition and affects the mevalonate pathway.
• Taxodione enhances sensitivity to conventional chemotherapy, offering a potential therapeutic strategy.